IN2014MN01495A - - Google Patents
Info
- Publication number
- IN2014MN01495A IN2014MN01495A IN1495MUN2014A IN2014MN01495A IN 2014MN01495 A IN2014MN01495 A IN 2014MN01495A IN 1495MUN2014 A IN1495MUN2014 A IN 1495MUN2014A IN 2014MN01495 A IN2014MN01495 A IN 2014MN01495A
- Authority
- IN
- India
- Prior art keywords
- metal
- formula
- group
- mixed
- patient
- Prior art date
Links
- 229910052784 alkaline earth metal Inorganic materials 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000004696 coordination complex Chemical class 0.000 abstract 2
- 230000001575 pathological effect Effects 0.000 abstract 2
- 229910052723 transition metal Inorganic materials 0.000 abstract 2
- 150000003624 transition metals Chemical class 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 150000002739 metals Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
- C07F19/005—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00 without metal-C linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261583377P | 2012-01-05 | 2012-01-05 | |
| US201261656178P | 2012-06-06 | 2012-06-06 | |
| US201261668679P | 2012-07-06 | 2012-07-06 | |
| US201261721575P | 2012-11-02 | 2012-11-02 | |
| PCT/IB2012/056959 WO2013102806A1 (en) | 2012-01-05 | 2012-12-04 | Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01495A true IN2014MN01495A (https=) | 2015-04-17 |
Family
ID=47559596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1495MUN2014 IN2014MN01495A (https=) | 2012-01-05 | 2012-12-04 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9187509B2 (https=) |
| EP (1) | EP2800755B1 (https=) |
| JP (2) | JP6131271B2 (https=) |
| KR (1) | KR102086022B1 (https=) |
| CN (2) | CN107353313B (https=) |
| AU (1) | AU2012364227B2 (https=) |
| BR (1) | BR112014016497B1 (https=) |
| CA (1) | CA2862736C (https=) |
| ES (1) | ES2683038T3 (https=) |
| HK (1) | HK1245276B (https=) |
| IN (1) | IN2014MN01495A (https=) |
| MX (1) | MX2014008247A (https=) |
| RU (2) | RU2622646C2 (https=) |
| WO (1) | WO2013102806A1 (https=) |
| ZA (1) | ZA201404904B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9187509B2 (en) | 2012-01-05 | 2015-11-17 | Pled Pharma AB | Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment |
| KR20150080616A (ko) * | 2012-11-02 | 2015-07-09 | 플레드파르마 에이비 | 암 치료 방법 |
| US10233205B2 (en) | 2015-08-07 | 2019-03-19 | Auburn University | Magnetic resonance imaging contrast agent capable of detecting hydrogen peroxide and reducing reactive oxygen species |
| EP3402475B1 (en) | 2016-01-11 | 2021-10-20 | Egetis Therapeutics AB | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
| CN110139673B (zh) * | 2016-11-14 | 2022-03-22 | 卡尔森图纳投资公司 | 使用非过渡金属配位的二吡哆基化合物以预防和治疗化疗诱发的psn |
| CN117279657A (zh) | 2021-05-18 | 2023-12-22 | 日本株式会社Ltt生物医药 | 用于治疗或预防伴随抗癌剂给药的障碍的医药组合物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223243A (en) | 1987-05-08 | 1993-06-29 | Salutar, Inc. | Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents |
| AR246956A1 (es) * | 1987-05-08 | 1994-10-31 | Salutar Inc | Compuesto quelante, un intermediario para preparar el mismo, y un procedimiento para preparar una composicion de medio de contraste. |
| US5091169A (en) | 1987-05-08 | 1992-02-25 | Salutar, Inc. | Dipyridoxyl phosphate NMRI contrast agent compositions |
| US5403834A (en) * | 1992-12-07 | 1995-04-04 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
| US6204259B1 (en) | 1993-01-14 | 2001-03-20 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
| GB9613182D0 (en) * | 1996-06-24 | 1996-08-28 | Nycomed Imaging As | Method |
| GB9727224D0 (en) | 1997-12-23 | 1998-02-25 | Nycomed Imaging As | Method |
| AU1770299A (en) | 1997-12-23 | 1999-07-19 | Nycomed Imaging As | Nitric oxide releasing chelating agents and their therapeutic use |
| FR2823977B1 (fr) | 2001-04-26 | 2006-12-01 | Univ Rene Descartes | Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif |
| DE10359628A1 (de) | 2003-12-18 | 2005-07-21 | Oxeno Olefinchemie Gmbh | Katalysator und Verfahren zur Herstellung von 1-Olefinen aus 2-Hydroxyalkanen |
| US20070148154A1 (en) | 2004-12-17 | 2007-06-28 | Universite Rene Descartes (Paris V) | Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs |
| BRPI0820832A2 (pt) * | 2007-12-14 | 2015-06-16 | Pledpharma Ab | Composto, uso de um composto, método de tratamento de câncer, composição farmacêutica, kit , e, uso de uma composição farmacêutica. |
| US8414866B2 (en) * | 2007-12-17 | 2013-04-09 | Ge Healthcare As | Method of magnetic resonance imaging of the heart with paramagnetic MN2+ |
| CN102481295A (zh) * | 2009-07-06 | 2012-05-30 | 普莱制药公司 | 利用锰配合物化合物与所述化合物之非锰配合物形式的组合的药物组合物和治疗方法 |
| US9187509B2 (en) * | 2012-01-05 | 2015-11-17 | Pled Pharma AB | Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment |
-
2012
- 2012-12-04 US US14/369,153 patent/US9187509B2/en active Active
- 2012-12-04 RU RU2014132184A patent/RU2622646C2/ru active
- 2012-12-04 BR BR112014016497-5A patent/BR112014016497B1/pt active IP Right Grant
- 2012-12-04 IN IN1495MUN2014 patent/IN2014MN01495A/en unknown
- 2012-12-04 CN CN201710588057.1A patent/CN107353313B/zh active Active
- 2012-12-04 RU RU2017119660A patent/RU2765805C2/ru active
- 2012-12-04 JP JP2014550770A patent/JP6131271B2/ja active Active
- 2012-12-04 CA CA2862736A patent/CA2862736C/en active Active
- 2012-12-04 KR KR1020147021727A patent/KR102086022B1/ko not_active Expired - Fee Related
- 2012-12-04 ES ES12815799.7T patent/ES2683038T3/es active Active
- 2012-12-04 CN CN201280070691.1A patent/CN104169291B/zh active Active
- 2012-12-04 AU AU2012364227A patent/AU2012364227B2/en active Active
- 2012-12-04 EP EP12815799.7A patent/EP2800755B1/en active Active
- 2012-12-04 WO PCT/IB2012/056959 patent/WO2013102806A1/en not_active Ceased
- 2012-12-04 MX MX2014008247A patent/MX2014008247A/es active IP Right Grant
-
2014
- 2014-07-02 ZA ZA2014/04904A patent/ZA201404904B/en unknown
-
2015
- 2015-10-26 US US14/922,555 patent/US9597334B2/en active Active
-
2017
- 2017-02-28 US US15/445,588 patent/US10111893B2/en active Active
- 2017-04-17 JP JP2017081176A patent/JP6316479B2/ja active Active
-
2018
- 2018-04-04 HK HK18104469.4A patent/HK1245276B/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2014000122A1 (en) | 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases | |
| PH12016500225B1 (en) | Novel quinoline-substituted compound | |
| PH12015502839A1 (en) | Antiviral compounds | |
| EA201301154A1 (ru) | Разветвленные производные 3-фенилпропионовой кислоты и их применение | |
| MX2014013660A (es) | Compuestos antivirales inhibidores del virus de hepatitis c (vhc) ns5b. | |
| IN2014MN01495A (https=) | ||
| PH12015501316A1 (en) | Heterocyclic compound | |
| MX352928B (es) | Compuestos de piridazina-amida. | |
| MY170262A (en) | Dicarboxylic acid compound | |
| MX2014011921A (es) | Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos. | |
| MX2014002936A (es) | Nuevos derivados de acido betulinico con actividad antiviral. | |
| MX361458B (es) | Compuestos de pirimido-piridazinona y uso de los mismos. | |
| NZ711343A (en) | Sodium salt of (2s, 5r)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1 ] octane-2-carboxylic acid and its preparation | |
| MY170637A (en) | Macrocyclic compound and methods for its production | |
| MX349548B (es) | Compuestos de tienopirimidina. | |
| MX2013008340A (es) | Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer. | |
| IN2014CN04449A (https=) | ||
| GEP20166448B (en) | Ophthalmic solution containing diquafosol, method for producing same, and method for preventing formation of insoluble precipitate | |
| IN2012DN05192A (https=) | ||
| MX351863B (es) | Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo. | |
| MX357763B (es) | Tratamiento para cancer pancreatico. | |
| MX2015002705A (es) | Compuestos de piridinona para usarse en terapia fotodinamica. | |
| TH149370A (th) | คาลมากาโฟดิเพอ, ตัวยาทางเคมีแบบใหม่, และสารประกอบเชิงซ้อนของโลหะผสมอื่นๆ, วิธีการของการเตรียม, องค์ประกอบ, และวิธีการของการรักษา (Calmangafodipir, a New Chemical Entity, and Other Mixed Metal Complexes, Methods of Preparation, Compositions, and Methods of Treatment) | |
| NZ725365A (en) | Antiviral compounds inhibitors of hcv ns5b | |
| UA92303C2 (ru) | КОМПЛЕКСНАЯ СОЛЬ Са-АЛЬДОНОВОЙ И АМИНОКАРБОНОВОЙ КИСЛОТ, ПРОЯВЛЯЮЩАЯ ПРОТИВООПУХОЛЕВОЕ ДЕЙСТВИЕ И СПОСОБ ЕЕ ПОЛУЧЕНИЯ |